The MPTP story

Journal of Parkinson's Disease

Volumn 7, Issue , 2017, Pages S11-S19

  Langston, J William ^a  

^a PARKINSON S INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; MONOAMINE OXIDASE B INHIBITOR; PARAQUAT; ROTENONE;

BASAL GANGLION; BRAIN DEPTH STIMULATION; DISEASE MODEL; DRUG DEVELOPMENT; DRUG MECHANISM; DRUG TARGETING; NEUROPROTECTION; NEUROTOXICITY; PARKINSON DISEASE; PRIMATE MODEL; PRIORITY JOURNAL; REVIEW; STRIATONIGRAL DEGENERATION; SUBTHALAMIC NUCLEUS; TRANSLATIONAL RESEARCH; ANIMAL; CORPUS STRIATUM; DRUG EFFECT; HISTORY; HUMAN; PARKINSONISM; SUBSTANTIA NIGRA;

1-METHYL-4-PHENYL-1,2,3,6-TETRAHYDROPYRIDINE; ANIMALS; CORPUS STRIATUM; DISEASE MODELS, ANIMAL; HISTORY, 20TH CENTURY; HUMANS; PARKINSON DISEASE; PARKINSONIAN DISORDERS; SUBSTANTIA NIGRA; TRANSLATIONAL MEDICAL RESEARCH;

EID: 85026491508     PISSN: 18777171     EISSN: 1877718X     Source Type: Journal    
DOI: 10.3233/JPD-179006     Document Type: Review

References (79)

1. Lewin R (1984) Trail of ironies to Parkinson's disease. Science, 224, 1083-1085.
2. Ballard PA, Tetrud JW, & Langston JW (1985) Permanent human parkinsonism due to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP): Seven cases. Neurology, 35, 949-956.
3. Stern Y, Tetrud JW, Martin WR, Kutner SJ, & Langston JW (1990) Cognitive change following MPTP exposure. Neurology, 40, 261-264.
4. Ziering A, & Lee J (1947) Piperidine derivatives; 1,3-dialkyl-4-aryl-4-acyloxypiperidines. J Org Chem, 12, 911-914.
5. Davis GC, Williams AC, Markey SP, Ebert MH, Caine ED, Reichert CM, & Kopin IJ (1979) Chronic Parkinsonism secondary to intravenous injection of meperidine analogues. Psychiatry Res, 1, 249-254.
6. Langston JW, Ballard P, Tetrud JW, & Irwin I (1983) Chronic Parkinsonism in humans due to a product of meperidine-analog synthesis. Science, 219, 979-980.
7. Langston JW, Irwin I, Langston EB, & Forno LS (1984) 1-Methyl-4-phenylpyridinium ion (MPP+): Identification of a metabolite of MPTP, a toxin selective to the substantia nigra. Neurosci Lett, 48, 87-92.
8. Markey SP, Johannessen JN, Chiueh CC, Burns RS, & HerkenhamMA(1984) Intraneuronal generation of a pyridinium metabolite may cause drug-induced parkinsonism. Nature, 311, 464-467.
9. Chiba K, Trevor A, & Castagnoli Jr N (1984) Metabolism of the neurotoxic tertiary amine, MPTP, by brain monoamine oxidase. Biochem Biophys Res Commun, 120, 574-578.
10. Castagnoli Jr N, Chiba K, & Trevor AJ (1985) Potential bioactivation pathways for the neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). Life Sci, 36, 225-230.
11. Heikkila RE, Manzino L, Cabbat FS, & Duvoisin RC (1984) Protection against the dopaminergic neurotoxicity of 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine by monoamine oxidase inhibitors. Nature, 311, 467-469.
12. Ransom BR, Kunis DM, Irwin I, & Langston JW (1987) Astrocytes convert the parkinsonism inducing neurotoxin, MPTP, to its active metabolite, MPP+. Neurosci Lett, 75, 323-328.
13. Shen RS, Abell CW, Gessner W, & Brossi A (1985) Serotonergic conversion ofMPTPand dopaminergic accumulation of MPP+. FEBS Lett, 189, 225-230.
14. Blanchard V, Raisman-Vozari R, Vyas S, Michel PP, Javoy-Agid F, Uhl G,&AgidY(1994) Differential expression of tyrosine hydroxylase and membrane dopamine transporter genes in subpopulations of dopaminergic neurons of the rat mesencephalon. Brain Res Mol Brain Res, 22, 29-38.
15. Lavoie B, & Parent A (1991) Dopaminergic neurons expressing calbindin in normal and parkinsonianmonkeys. Neuroreport, 2, 601-604.
16. Ramsay RR, Dadgar J, Trevor A, & Singer TP (1986) Energy-driven uptake of N-methyl-4-phenylpyridine by brain mitochondria mediates the neurotoxicity of MPTP. Life Sci, 39, 581-588.
17. Ramsay RR, Salach JI, & Singer TP (1986) Uptake of the neurotoxin 1-methyl-4-phenylpyridine (MPP+) by mitochondria and its relation to the inhibition of the mitochondrial oxidation of NAD+-linked substrates by MPP+. Biochem Biophys Res Commun, 134, 743-748.
18. Ramsay RR, Kowal AT, Johnson MK, Salach JI, & Singer TP (1987) The inhibition site of MPP+, the neurotoxic bioactivation product of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine is near the Q-binding site of NADH dehydrogenase. Arch Biochem Biophys, 259, 645-649.
19. Chan P, DeLanney LE, Irwin I, Langston JW, & DiMonte D (1991) Rapid ATP loss caused by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in mouse brain. J Neurochem, 57, 348-351.
20. Speciale SG, Liang CL, Sonsalla PK, Edwards RH, & German DC (1998) The neurotoxin 1-methyl-4-phenylpyridinium is sequestered within neurons that contain the vesicular monoamine transporter. Neuroscience, 84, 1177-1185.
21. Chen MK, Kuwabara H, Zhou Y, Adams RJ, Brasic JR, McGlothan JL,VerinaT, Burton NC, Alexander M,Kumar A,WongDF,&GuilarteTR(2008)VMAT2 and dopamine neuron loss in a primate model of Parkinson's disease. J Neurochem, 105, 78-90.
22. Lotharius J, & Brundin P (2002) Pathogenesis of Parkinson's disease: Dopamine, vesicles and alpha-synuclein. Nat Rev Neurosci, 3, 932-942.
23. Schapira AH, Cooper JM, Dexter D, Clark JB, Jenner P,& Marsden CD (1990) Mitochondrial complex I deficiency in Parkinson's disease. J Neurochem, 54, 823-827.
24. SchapiraAH,MannVM,Cooper JM,Dexter D, Daniel SE, Jenner P, Clark JB, & Marsden CD (1990) Anatomic and disease specificity of NADH CoQ1 reductase (complex I) deficiency in Parkinson's disease. J Neurochem, 55, 2142-2145.
25. Bindoff LA, Birch-Machin MA, Cartlidge NE, Parker Jr WD, & Turnbull DM (1991) Respiratory chain abnormalities in skeletal muscle from patients with Parkinson's disease. J Neurol Sci, 104, 203-208.
26. Haas RH, Nasirian F, Nakano K, Ward D, Pay M, Hill R, & Shults CW (1995) Low platelet mitochondrial complex I and complex II/III activity in early untreated Parkinson's disease. Ann Neurol, 37, 714-722.
27. Schapira AH, Holt IJ, Sweeney M, Harding AE, Jenner P, & Marsden CD (1990) Mitochondrial DNA analysis in Parkinson's disease. Mov Disord, 5, 294-297.
28. Di MonteDA(1991) MitochondrialDNAand Parkinson's disease. Neurology, 41, 38-42; discussion 42-33.
29. Sanders LH, Laganiere J, Cooper O, Mak SK, Vu BJ, Huang YA, Paschon DE, Vangipuram M, Sundararajan R, Urnov FD, Langston JW, Gregory PD, Zhang HS, Greenamyre JT, Isacson O, & Schule B (2014) LRRK2 mutations cause mitochondrial DNA damage in iPSCderived neural cells from Parkinson's disease patients: Reversal by gene correction. Neurobiol Dis, 62, 381-386.
30. Gehrke S, Wu Z, Klinkenberg M, Sun Y, Auburger G, Guo S, & Lu B (2015) PINK1 and Parkin control localized translation of respiratory chain component mRNAs on mitochondria outer membrane. Cell Metab, 21, 95-108.
31. SchapiraAH(2012) Targeting mitochondria for neuroprotection in Parkinson's disease. Antioxid Redox Signal, 16, 965-973.
32. Parkinson Study Group QEI, Beal MF, Oakes D, Shoulson I, Henchcliffe C, Galpern WR, Haas R, Juncos JL, Nutt JG, Voss TS, Ravina B, Shults CM, Helles K, Snively V, Lew MF, Griebner B, Watts A, Gao S, Pourcher E, Bond L, Kompoliti K, Agarwal P, Sia C, Jog M, Cole L, Sultana M, Kurlan R, Richard I, Deeley C, Waters CH, Figueroa A, Arkun A, BrodskyM, Ondo WG, Hunter CB, Jimenez-Shahed J, Palao A, Miyasaki JM, So J, Tetrud J, Reys L, Smith K, Singer C, Blenke A, Russell DS, Cotto C, Friedman JH, Lannon M, Zhang L, Drasby E, Kumar R, Subramanian T, Ford DS, Grimes DA, Cote D, Conway J, Siderowf AD, Evatt ML, Sommerfeld B, Lieberman AN, Okun MS, Rodriguez RL, Merritt S, Swartz CL, Martin WR, King P, Stover N, Guthrie S, Watts RL, Ahmed A, Fernandez HH, Winters A, Mari Z, Dawson TM, Dunlop B, Feigin AS, Shannon B, Nirenberg MJ, Ogg M, Ellias SA, Thomas CA, Frei K, Bodis-Wollner I, Glazman S, Mayer T, Hauser RA, Pahwa R, Langhammer A, Ranawaya R, Derwent L, Sethi KD, Farrow B, Prakash R, Litvan I, Robinson A, Sahay A, Gartner M, Hinson VK, Markind S, Pelikan M, Perlmutter JS, Hartlein J, Molho E, Evans S, Adler CH, Duffy A, Lind M, Elmer L, Davis K, Spears J,Wilson S, Leehey MA, Hermanowicz N, Niswonger S, Shill HA, Obradov S, Rajput A, Cowper M, Lessig S, Song D, Fontaine D, Zadikoff C, Williams K, Blindauer KA, Bergholte J, Propsom CS, Stacy MA, Field J, Mihaila D, Chilton M, Uc EY, Sieren J, Simon DK, Kraics L, Silver A, Boyd JT, Hamill RW, Ingvoldstad C, Young J, Thomas K, Kostyk SK, Wojcieszek J, Pfeiffer RF, Panisset M, Beland M, Reich SG, Cines M, Zappala N, Rivest J, Zweig R, Lumina LP, Hilliard CL, Grill S, Kellermann M, Tuite P, Rolandelli S, Kang UJ, Young J, Rao J, Cook MM, Severt L, & Boyar K (2014) A randomized clinical trial of high-dosage coenzyme Q10 in early Parkinson disease: No evidence of benefit. JAMA Neurol, 71, 543-552.
33. Snow BJ, Rolfe FL, Lockhart MM, Frampton CM, O'Sullivan JD, Fung V, Smith RA, Murphy MP, Taylor KM, & Protect Study G (2010) A double-blind, placebo-controlled study to assess the mitochondriatargeted antioxidant MitoQ as a disease-modifying therapy in Parkinson's disease. Mov Disord, 25, 1670-1674.
34. Jenner P, & Langston JW (2011) Explaining ADAGIO: A critical review of the biological basis for the clinical effects of rasagiline. Mov Disord, 26, 2316-2323.
35. Burns RS, Markey SP, Phillips JM, & Chiueh CC (1984) The neurotoxicity of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in the monkey and man. Can J Neurol Sci, 11, 166-168.
36. Langston JW, Langston EB, & Irwin I (1984) MPTPinduced parkinsonism in human and non-human primates-clinical and experimental aspects. Acta Neurol Scand Suppl, 100, 49-54.
37. Langston JW, Forno LS, Rebert CS, & Irwin I (1984) Selective nigral toxicity after systemic administration of 1-methyl-4-phenyl-1,2,5,6-tetrahydropyrine (MPTP) in the squirrel monkey. Brain Res, 292, 390-394.
38. Jacobowitz DM, Burns RS, Chiueh CC, & Kopin IJ (1984) N-methyl-4-phenyl-1,2,3,6-tetra-hydropyridine (MPTP) causes destruction of the nigrostriatal but not the mesolimbic dopamine system in the monkey. Psychopharmacol Bull, 20, 416-422.
39. Fox SH, & Brotchie JM (2010) The MPTP-lesioned non-human primate models of Parkinson's disease. Past, present, and future. Prog Brain Res, 184, 133-157.
40. Quik M, Cox H, Parameswaran N, O'Leary K, Langston JW, & Di Monte D (2007) Nicotine reduces levodopainduced dyskinesias in lesioned monkeys. Ann Neurol, 62, 588-596.
41. Riachi NJ, Harik SI, Kalaria RN, & Sayre LM (1988) On the mechanisms underlying 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine neurotoxicity. II. Susceptibility among mammalian species correlates with the toxin's metabolic patterns in brain microvessels and liver. J Pharmacol Exp Ther, 244, 443-448.
42. Riachi NJ, LaManna JC, & Harik SI (1989) Entry of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine into the rat brain. J Pharmacol Exp Ther, 249, 744-748.
43. Heikkila RE, Cabbat FS, Manzino L, & Duvoisin RC (1984) Effects of 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine on neostriatal dopamine in mice. Neuropharmacology, 23, 711-713.
44. McKinley ET, Baranowski TC, Blavo DO, Cato C, Doan TN, & Rubinstein AL (2005) Neuroprotection of MPTPinduced toxicity in zebrafish dopaminergic neurons. Brain Res Mol Brain Res, 141, 128-137.
45. Braungart E, Gerlach M, Riederer P, Baumeister R, & Hoener MC (2004) Caenorhabditis elegans MPP+ model of Parkinson's disease for highthroughput drug screenings. Neurodegener Dis, 1, 175-183.
46. Wang YM, Pu P, & Le WD (2007) ATP depletion is the major cause of MPP+ induced dopamine neuronal death and worm lethality in alpha-synuclein transgenic C. elegans. Neurosci Bull, 23, 329-335.
47. Barbeau A, Dallaire L, Buu NT, Veilleux F, Boyer H, de Lanney LE, Irwin I, Langston EB, & Langston JW (1985) New amphibian models for the study of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). Life Sci, 36, 1125-1134.
48. Manning-Bog AB, & Langston JW (2007) Model fusion, the next phase in developing animal models for Parkinson's disease. Neurotox Res, 11, 219-240.
49. Przedborski S, Kostic V, Jackson-Lewis V, Naini AB, Simonetti S, Fahn S, Carlson E, Epstein CJ, & Cadet JL (1992) Transgenic mice with increased Cu/Zn-superoxide dismutase activity are resistant to N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurotoxicity. J Neurosci, 12, 1658-1667.
50. Trimmer PA, Smith TS, Jung AB, & Bennett Jr JP (1996) Dopamine neurons from transgenic mice with a knockout of the p53 gene resist MPTP neurotoxicity. Neurodegeneration, 5, 233-239.
51. Takahashi N, Miner LL, Sora I, Ujike H, Revay RS, Kostic V, Jackson-Lewis V, Przedborski S, & Uhl GR (1997) VMAT2 knockout mice: Heterozygotes display reduced amphetamine-conditioned reward, enhanced amphetamine locomotion, and enhanced MPTP toxicity. Proc Natl Acad Sci U S A, 94, 9938-9943.
52. Offen D, Beart PM, Cheung NS, Pascoe CJ, Hochman A, Gorodin S, Melamed E, Bernard R, & Bernard O (1998) Transgenic mice expressing human Bcl-2 in their neurons are resistant to 6-hydroxydopamine and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine neurotoxicity. Proc Natl Acad Sci U S A, 95, 5789-5794.
53. Ebadi M, Brown-Borg H, El Refaey H, Singh BB, Garrett S, Shavali S, & Sharma SK (2005) Metallothionein mediated neuroprotection in genetically engineered mouse models of Parkinson's disease. Brain Res Mol Brain Res, 134, 67-75.
54. Chen PC, Vargas MR, Pani AK, Smeyne RJ, Johnson DA, Kan YW, & Johnson JA (2009) Nrf2-mediated neuroprotection in the MPTP mouse model of Parkinson's disease: Critical role for the astrocyte. Proc Natl Acad Sci U S A, 106, 2933-2938.
55. Bian M, Liu J, Hong X, Yu M, Huang Y, Sheng Z, Fei J, & Huang F (2012) Overexpression of parkin ameliorates dopaminergic neurodegeneration induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in mice. PLoS One, 7, e39953.
56. Langston JW, Irwin I, Langston EB, & Forno LS (1984) Pargyline prevents MPTP-induced parkinsonism in primates. Science, 225, 1480-1482.
57. Cohen G, Pasik P, Cohen B, Leist A, Mytilineou C, & YahrMD(1984) Pargyline and deprenyl prevent the neurotoxicity of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in monkeys. Eur J Pharmacol, 106, 209-210.
58. Sandler M, Glover V, Ashford A, & Esmail A (1980) The inhibition of tyramine oxidation and the tyramine hypertensive response ("cheese effect") may be independent phenomena. J Neural Transm, 48, 241-247.
59. Sandler M, Glover V, Ashford A, & Stern GM (1978) Absence of "cheese effect" during deprenyl therapy: Some recent studies. J Neural Transm, 43, 209-215.
60. Tetrud JLJ (1989) The effect of Deprenyl (Selegiline) on the Natural History of PD. ScienceMag, 1989.pdf. Science Mag.
61. (1989) Effect of deprenyl on the progression of disability in early Parkinson's disease. The Parkinson Study Group. N Engl J Med 321, 1364-1371.
62. Olanow CW, Rascol O, Hauser R, Feigin PD, Jankovic J, Lang A, Langston W, Melamed E, Poewe W, Stocchi F, Tolosa E, & Investigators AS (2009) A double-blind, delayed-start trial of rasagiline in Parkinson's disease. N Engl J Med, 361, 1268-1278.
63. Schapira AH, McDermott MP, Barone P, Comella CL, Albrecht S, Hsu HH, Massey DH, Mizuno Y, Poewe W, Rascol O, & Marek K (2013) Pramipexole in patients with early Parkinson's disease (PROUD): A randomised delayed-start trial. Lancet Neurol, 12, 747-755.
64. DeLong MR (1990) Primate models of movement disorders of basal ganglia origin. Trends Neurosci, 13, 281-285.
65. Bergman H, Wichmann T, Karmon B, & DeLong MR (1994) The primate subthalamic nucleus. II. Neuronal activity in the MPTP model of parkinsonism. J Neurophysiol, 72, 507-520.
66. Bergman H,Wichmann T,&DeLongMR(1990) Reversal of experimental parkinsonism by lesions of the subthalamic nucleus. Science, 249, 1436-1438.
67. Benabid AL, Pollak P, Gross C, Hoffmann D, Benazzouz A, Gao DM, Laurent A, Gentil M,&Perret J (1994) Acute and long-term effects of subthalamic nucleus stimulation in Parkinson's disease. Stereotact Funct Neurosurg, 62, 76-84.
68. Wichmann T, DeLong MR, Guridi J, & Obeso JA (2011) Milestones in research on the pathophysiology of Parkinson's disease. Mov Disord, 26, 1032-1041.
69. Goldman SM (2014) Environmental toxins and Parkinson's disease. Annu Rev Pharmacol Toxicol, 54, 141-164.
70. Sandy MS, Di Monte D, Cohen P, & Smith MT (1988) Role of active oxygen in paraquat and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) cytotoxicity. Basic Life Sci, 49, 795-801.
71. Tanner CM (2010) Advances in environmental epidemiology. Mov Disord, 25(Suppl 1), S58-S62.
72. Goldman SM, Kamel F, RossGW, Bhudhikanok GS, Hoppin JA,Korell M, Marras C, Meng C, Umbach DM, Kasten M, Chade AR, Comyns K, Richards MB, SandlerDP, Blair A, Langston JW, & Tanner CM (2012) Genetic modification of the association of paraquat and Parkinson's disease. Mov Disord, 27, 1652-1658.
73. Betarbet R, Sherer TB, MacKenzie G, Garcia-Osuna M, PanovAV,&Greenamyre JT (2000) Chronic systemic pesticide exposure reproduces features of Parkinson's disease. Nat Neurosci, 3, 1301-1306.
74. Ramsay RR, Krueger MJ, Youngster SK, Gluck MR, Casida JE, & Singer TP (1991) Interaction of 1-methyl-4-phenylpyridinium ion (MPP+) and its analogs with the rotenone/piericidin binding site ofNADHdehydrogenase. J Neurochem, 56, 1184-1190.
75. Polymeropoulos MH, Lavedan C, Leroy E, Ide SE, Dehejia A, Dutra A, Pike B, Root H, Rubenstein J, Boyer R, Stenroos ES, Chandrasekharappa S, Athanassiadou A, Papapetropoulos T, Johnson WG, Lazzarini AM, Duvoisin RC, Di Iorio G, Golbe LI, & Nussbaum RL (1997) Mutation in the alpha-synuclein gene identified in families with Parkinson's disease [see comments]. Science, 276, 2045-2047.
76. Purisai MG, McCormack AL, Langston WJ, Johnston LC, &Di Monte DA (2005) Alpha-synuclein expression in the substantia nigra of MPTP-lesioned non-human primates. Neurobiol Dis, 20, 898-906.
77. Nussbaum RL (2017) The identification of alphasynuclein as the first Parkinson disease gene. J Parkinsons Dis, 7, S45-S51.
78. Hauser RA, Li R, Pérez A, Ren X, Weintraub D, Elm J, Goudreau JL, Morgan JC, Fang JY, Aminoff MJ, Christine CW, Dhall R, Umeh CC, Boyd JT, Stover N, Leehey M, Zweig RM, Nicholas AP, Bodis-Wollner I, Willis A, Kieburtz K, Tilley BC and for the NINDS NET-PD Investigators (2017) Longer duration of MAO-B inhibitor exposure is associated with less clinical decline in Parkinson's disease: An analysis of NET-PD LS1. J Parkinsons Dis, 7, 117-127.
79. Hariz M (2017) My 25 stimulating years with DBS in Parkinson's disease. J Parkinsons Dis, 7, S35-S43.